How Are Gene-Editing Therapies Regulated in the United States?

Gene-editing therapies are regulated in the United States by FDA's Center for Biologics Evaluation and Research as human gene therapy products, reviewed through the Investigational New Drug pathway under 21 CFR 312.23. The operative document is FDA's January 2024 guidance on editing of somatic cells, and the framework has one approved product so far: Casgevy, cleared December 8, 2023.

Which FDA office reviews gene-editing products?

Gene-editing therapies are handled by CBER's Office of Therapeutic Products, the same office that oversees the licensed cell and gene therapy portfolio. FDA's guidance on human gene therapy products incorporating human genome editing, finalized in January 2024, states that it provides recommendations to sponsors developing such products for somatic cells. The document covers product design, manufacturing and testing, nonclinical safety assessment, and clinical trial design, per the guidance text. The office also hosted a public webinar on February 29, 2024 to walk through the final document's key considerations.

The scope matters for sponsors. The guidance applies to editing of somatic cells, the category that covers approved products such as Casgevy (exagamglogene autotemcel). Germline editing, which would alter inherited DNA, sits outside any permissible development path in the United States, and no IND for it can lawfully proceed. That boundary is what makes the somatic-cell framing of the guidance the operative rule for every CRISPR, base-editing, and prime-editing program now in the clinic.

What must an IND for an edited therapy contain?

An IND must give FDA enough information to assess the safety and quality of the investigational product before human dosing begins. For genome-editing products, the January 2024 guidance says the submission should address four areas: product design, product manufacturing and testing, nonclinical safety assessment, and clinical trial design, as required under 21 CFR 312.23. Each area carries editing-specific expectations that distinguish these files from ordinary biologics submissions.

Product design questions include the editing mechanism, the specificity of the nuclease or editor for its target site, and off-target analysis. Manufacturing sections must characterize the edited cell population or vector batch, because the editing step introduces variability that traditional release testing does not fully capture. Nonclinical programs are expected to measure on-target and off-target editing in relevant models, and clinical protocols must define long-term follow-up consistent with gene therapy rules. FDA has separate long-term follow-up expectations for gene therapies generally, and edited products inherit them.

What did the Casgevy approval establish?

Casgevy became the first FDA-approved therapy to use a genome-editing technology when the agency approved it on December 8, 2023, per the FDA press announcement. The same action approved Lyfgenia, a lentiviral gene therapy, for sickle cell disease in patients 12 years and older. Both are cell-based gene therapies, but only Casgevy uses CRISPR/Cas9 editing, which FDA described as a novel genome editing technology at the time of approval.

The approval matters for the regulatory map because it moved editing from guidance documents into a licensed product with a label, a risk evaluation and mitigation strategy, and postmarketing commitments. Sickle cell disease affects approximately 100,000 people in the U.S., per the same announcement, and the approved indication covers patients 12 years and older with recurrent vaso-occlusive crises. Every subsequent editing program is now benchmarked against that first approval file.

What does the path from IND to approval look like?

The route for a gene-editing therapy follows the standard biologics sequence, with editing-specific data layered in. In outline:

1. Pre-IND meetings with CBER's Office of Therapeutic Products to align on off-target analysis and study design.
2. IND submission under 21 CFR 312.23 covering product design, manufacturing and testing, nonclinical safety, and the clinical protocol.
3. Phase 1/2 dosing with long-term follow-up planned from the start.
4. Pivotal trials in the target indication, potentially with expedited program designations where criteria are met.
5. Biologics License Application and review.
6. Approval with postmarketing requirements, as occurred with Casgevy.

How many edited or gene-modified products are licensed today?

FDA maintains a public list of approved cellular and gene therapy products that shows the licensed landscape, including Casgevy, AAV-based gene therapies such as Hemgenix and Elevidys, and the CAR-T family. The approved products list is the reference for what has actually crossed the finish line, as distinct from the larger set of active INDs. The list is maintained by the Office of Therapeutic Products and is updated as new licenses are granted.

The gap between that list and the pipeline is wide. Dozens of editing programs are in clinical development, but the licensed set remains small, and each approval has rested on indication-specific data. For readers tracking the field, the practical rule is unchanged: the guidance defines what FDA expects at IND, and the Casgevy file defines what a full approval package looks like.

What is the difference between ex vivo and in vivo editing?

Ex vivo editing means cells are collected from the patient or a donor, edited in a laboratory, and returned as a manufactured therapeutic. Casgevy follows this model: a patient's own stem cells are edited outside the body and reinfused after conditioning. The manufacturing burden sits with the treatment developer, and each patient effectively becomes a production batch, which shapes both cost and scale.

In vivo editing delivers the editing machinery directly into the patient, typically packaged in a lipid nanoparticle or a viral vector. No cell manufacturing facility is needed, but the distribution question inverts: the editing components must reach the right tissue and avoid the wrong ones. The January 2024 guidance applies to both configurations, because its four IND content areas, from product design through clinical trial design, are the same questions asked of either format.

The distinction also drives safety review. For ex vivo products, off-target analysis happens on the manufactured cell lot before infusion. For in vivo products, off-target editing can only be assessed indirectly, through nonclinical studies and biodistribution data, which is why the guidance treats product design and nonclinical safety assessment as connected rather than separate chapters.

What does somatic mean, and why does the word carry legal weight?

Somatic cells are all the cells of the body except sperm and eggs. Editing them changes only the treated patient, and the change is not inherited. FDA's guidance scopes itself to genome editing of human somatic cells, and that single word defines the lawful universe of the field in the United States.

Germline editing, which would alter embryos, sperm, or eggs and pass changes to descendants, is prohibited from federal funding by congressional rider and has no development pathway at FDA. The distinction is not a technicality in review; it is the boundary of what an IND can propose. Sponsors describe their target tissue accordingly, and reviewers read that language closely.

For readers comparing national frameworks, the somatic-only rule is broadly shared across regulators, though enforcement mechanisms differ. What matters at IND is that the editing target, the delivery route, and the cell type are stated explicitly enough that the somatic scope of the proposal is unambiguous.

How does the review calendar usually run?

An IND becomes active by operation of law 30 days after FDA receives it, unless the agency places the study on clinical hold, and gene-editing programs follow that rule like any other investigational biologic. The pre-IND meeting is where most of the editing-specific negotiation happens, months before the submission. Sponsors present off-target analysis plans, candidate selection rationale, and the intended population, and the agency's advice narrows what the IND must contain.

From first-in-human dosing onward, the development program resembles other serious-disease biologics: dose-finding, then pivotal trials sized to the indication, then a biologics license application. Gene therapies also carry long-term follow-up expectations, because integration and durable expression raise questions that standard six-month safety windows cannot answer. Follow-up plans are typically drafted at IND, not negotiated after approval.

The practical implication for anyone scheduling around an editing program is that the IND submission is a predictable, documentable milestone, but the trial duration is indication-driven. The Casgevy file, built on a pivotal study in patients 12 and older with recurrent vaso-occlusive crises, shows the shape of an approval package, not a universal timeline.